Sort by
Pharmacology, Toxicology and Pharmaceutical Science
25 Hydroxyvitamin D
14%
4-Aminopyridine
14%
Acute Graft Versus Host Disease
14%
Acute Heart Infarction
57%
Adverse Outcome
14%
Anaphylaxis
14%
Antilipemic Agent
14%
Brain Atrophy
28%
Brain Natriuretic Peptide
19%
Cancer Survival
14%
Candida Auris
14%
Cardiovascular Disease
78%
Cohort Study
28%
Comorbidity
20%
Congestive Heart Failure
30%
Cotransporter
14%
COVID-19 Vaccine
14%
Diabetes Mellitus
15%
Diseases
27%
Dyslipidemia
34%
Empagliflozin
51%
Ertugliflozin
14%
Exendin 4
42%
Fatty Acid
14%
Global Disease Burden
47%
Glucocorticoid
14%
Heart Disease
14%
Hemoglobin A1c
27%
Homocysteine
17%
Hyperglycemia
14%
Hypovitaminosis D
14%
Infection
17%
Ketone Bodies
14%
Low Back Pain
21%
Low Density Lipoprotein Cholesterol
16%
Messenger RNA
14%
Mild Cognitive Impairment
15%
Musculoskeletal Disease
14%
Non Communicable Disease
21%
Non Insulin Dependent Diabetes Mellitus
100%
Pandemic
14%
Placebo
32%
Prevalence
66%
Randomized Controlled Trial
53%
Retrospective Study
14%
Sodium Glucose Cotransporter 2 Inhibitor
27%
Thyroid Cancer
14%
Tolerable Daily Intake
14%
Urokinase Receptor
14%
Vitamin D Deficiency
14%
Medicine and Dentistry
4-Aminopyridine
14%
Acute Graft Versus Host Disease
14%
Acute Heart Infarction
42%
Adverse Outcome
14%
Amphotericin
14%
Antibiotic Resistance
14%
Breast Cancer Survival
14%
Cardiac Marker
14%
Cardiometabolic Risk
14%
Cardiovascular Disease
37%
Cardiovascular System
28%
Congestive Heart Failure
21%
COVID-19
28%
Diabetes
25%
Diabetology
28%
Disability Adjusted Life Years
14%
Diseases
28%
Dyslipidemia
14%
Echinocandin
14%
Empagliflozin
30%
Exenatide
14%
Exercise Intervention
14%
Fluconazole
14%
Global Disease Burden
30%
Glomerular Filtration Rate
14%
Glucocorticoid
14%
Health Care
14%
Hyperglycemia
14%
Infection Control
14%
Intensive Care Unit
14%
Intermittent Fasting
14%
Interneuron
14%
Ketone Bodies
14%
Left Ventricle
14%
Maturity Onset Diabetes of the Young
38%
Metabolic Syndrome
28%
Multidrug Resistance
14%
Musculoskeletal Disease
14%
Non Communicable Disease
21%
Post-Hoc Analysis
14%
Prevalence
28%
Prospective Cohort Study
14%
Pyrrole Derivative
14%
Randomized Controlled Trial
14%
SEQUEST
14%
Sodium Glucose Cotransporter 2 Inhibitor
22%
Systematic Review
14%
Thyroid Cancer
14%
Urokinase Receptor
14%
Uterine Artery Embolization
14%
Nursing and Health Professions
Acute Heart Infarction
14%
Adverse Event
5%
Alpha Rhythm
14%
Anthropometry
7%
Antidiabetic Agent
14%
Antilipemic Agent
14%
Brain Natriuretic Peptide
7%
Cardiovascular Disease
71%
Cardiovascular Risk
8%
Central Obesity
21%
Chronic Kidney Failure
14%
Diastolic Blood Pressure
14%
Dysglycemia
19%
Dyslipidemia
34%
Empagliflozin
14%
Estimated Glomerular Filtration Rate
16%
Exendin 4
14%
Fatality
14%
Health Care Personnel
14%
Healthcare System
14%
Heart Left Ventricle Ejection Fraction
14%
Heart Left Ventricle Enddiastolic Volume
14%
Hypoglycemia
14%
Intermittent Fasting
14%
Ketone Bodies
14%
Metabolic Syndrome X
14%
Mild Cognitive Impairment
14%
Monotherapy
7%
Non Communicable Disease
7%
Odds Ratio
9%
Patient with Type 2 Diabetes
14%
Personal Trainer
14%
Pharmacovigilance
14%
Placebo
7%
Post Hoc Analysis
14%
Prevalence
14%
Receiver Operating Characteristic
7%
Sodium Glucose Cotransporter 2 Inhibitor
10%
Systematic Review
14%
Systolic Blood Pressure
8%
Tobacco Smoking
14%
Urokinase Receptor
14%
Volunteer
7%
